Equities

BlackRock Health Sciences Term Trust

BlackRock Health Sciences Term Trust

Actions
FinancialsClosed End Investments
  • Price (USD)16.12
  • Today's Change0.19 / 1.19%
  • Shares traded231.16k
  • 1 Year change+12.65%
  • Beta0.9224
Data delayed at least 15 minutes, as of Sep 20 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year BlackRock Health Sciences Term Trust grew revenues 42.99% from 9.19m to 13.15m while net income improved from a loss of 682.72m to a gain of 69.86m.
Gross margin-65.26%
Net profit margin-156.92%
Operating margin-83.35%
Return on assets-1.11%
Return on equity-1.15%
Return on investment-1.12%
More ▼

Cash flow in USDView more

In 2023, BlackRock Health Sciences Term Trust increased its cash reserves by 1,165.70%, or 421.05k. The company earned 224.79m from its operations for a Cash Flow Margin of 1,709.95%. In addition the company used on investing activities and also paid 224.37m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share17.56
Tangible book value per share17.56
More ▼

Balance sheet in USDView more

BlackRock Health Sciences Term Trust uses little debt in its capital structure as supported by a debt to capital ratio of 0.00%.
Current ratio--
Quick ratio--
Total debt/total equity0.00001
Total debt/total capital0.00001
More ▼

Growth rates in USD

Year on year, growth in dividends per share fell -9.05% while earnings per share excluding extraordinary items rose 110.53%.
Div yield(5 year avg)6.39%
Div growth rate (5 year)--
Payout ratio (TTM)--
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-112.17
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.